CoChat

First Outpatient Evaluation of a Tubeless Automated Insulin Delivery System with Customizable Glucose Targets in Children and Adults with Type 1 Diabetes

Open access
Forlenza, Gregory P., Buckingham, Bruce A., Brown, Sue A., Bode, Bruce W., Levy, Carol J., Criego, Amy B., Wadwa, R. Paul, Cobry, Erin C., Slover, Robert J., Messer, Laurel H., Berget, Cari, McCoy, Susan, Ekhlaspour, Laya, Kingman, Ryan S., Voelmle, Mary K., Boyd, Jennifer, O'Malley, Grenye, Grieme, Aimee, Kivilaid, Kaisa, Kleve, Krista, Dumais, Bonnie, Vienneau, Todd, Huyett, Lauren M., Lee, Joon Bok, O'Connor, Jason, Benjamin, Eric, Ly, Trang T. · 2021 · Diabetes Technology & Therapeutics
Cited by 78

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

Background: The objective of this study was to assess the safety and effectiveness of the first commercial configuration of a tubeless automated insulin delivery system, Omnipod ® 5, in children (6–13.9 years) and adults (14–70 years) with type 1 diabetes (T1D) in an outpatient setting. Materials and Methods: This was a single-arm, multicenter, prospective clinical study. Data were collected over a 14-day standard therapy (ST) phase followed by a 14-day hybrid closed-loop (HCL) phase, where participants ( n = 36) spent 72 h at each of three prespecified glucose targets (130, 140, and 150 mg/dL, 9 days total) then 5 days with free choice of glucose targets (110–150 mg/dL) using the Omnipod 5. Remote safety monitoring alerts were enabled during the HCL phase. Primary endpoints were difference in time in range (TIR) (70–180 mg/dL) between ST and HCL phases and proportion of participants reporting serious device-related adverse events. Results: Mean TIR was significantly higher among children in the free-choice period overall (64.9% ± 12.2%, P < 0.01) and when using a 110 mg/dL target (71.2% ± 10.2%, P < 0.01), a 130 mg/dL target (61.5% ± 7.7%, P < 0.01), and a 140 mg/dL target (64.8% ± 11.6%, P < 0.01), and among adults using a 130 mg/dL target (75.1% ± 11.6%, P < 0.05), compared to the ST phase (children: 51.0% ± 13.3% and adults: 65.6% ± 15.7%). There were no serious device-related adverse events reported during the HCL phase, nor were there episodes of severe hypoglycemia or diabetic ketoacidosis. Conclusion: The Omnipod 5 System was safe and effective when used at glucose targets from 110 to 150 mg/dL for 14 days at home in children and adults with T1D.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/dia.2020.0546

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 78

Metadata

Authors
Forlenza, G. P., Buckingham, B. A., Brown, S. A., Bode, B. W., Levy, C. J., Criego, A. B., Wadwa, R. P., Cobry, E. C., Slover, R. J., Messer, L. H., Berget, C., McCoy, S., Ekhlaspour, L., Kingman, R. S., Voelmle, M. K., Boyd, J., O'Malley, G., Grieme, A., Kivilaid, K., Kleve, K., Dumais, B., Vienneau, T., Huyett, L. M., Lee, J. B., O'Connor, J., Benjamin, E., & Ly, T. T.
Venue
Diabetes Technology & Therapeutics
Published
2021-06-01
Volume
23
Issue
6
Pages
410-424
ISSN
  • 1520-9156 (ISSN-L)
  • 1557-8593
OpenAlex
W3111530450
Cited by
78
References
20
FWCI
8.12
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: First Outpatient Evaluation of a Tubeless Automated Insulin Delivery System with Customizable Glucose Targets in Children and Adults with Type 1 Diabetes. https://app.cochat.ai/papers/10.1089/dia.2020.0546
The paper
Forlenza, G. P., Buckingham, B. A., Brown, S. A., Bode, B. W., Levy, C. J., Criego, A. B., Wadwa, R. P., Cobry, E. C., Slover, R. J., Messer, L. H., Berget, C., McCoy, S., Ekhlaspour, L., Kingman, R. S., Voelmle, M. K., Boyd, J., O'Malley, G., Grieme, A., Kivilaid, K., . . . Ly, T. T. (2021). First Outpatient Evaluation of a Tubeless Automated Insulin Delivery System with Customizable Glucose Targets in Children and Adults with Type 1 Diabetes. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2020.0546

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.